Compare AU
Compare DRUG vs. GRNV
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the MSCI Aussie Sustainable (GRNV). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | GRNV | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 580 |
Median incremental investment | $967.00 | $670.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,905.75 | $1,415.06 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DRUG | GRNV | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | GRNV.AX was created on 2016-04-27 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. GRNV.AX gives investors access to a diversified portfolio of sustainable Australian companies selected on the basis of in-depth analysis by world leading research agency MSCI ESG Research. GRNV.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | Westpac Banking Corp (5.04 %) Goodman Group (5.01 %) Telstra Group Ltd (4.99 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Financials (29.07 %) Industrials (20.16 %) Real Estate (12.06 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | Australia (94.04 %) New Zealand (3.05 %) United States (2.91 %) |
Management fee | 0.57 % | 0.35 % |
Key Summary
DRUG | GRNV | |
|---|---|---|
Issuer | BetaShares | VanEck |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | MSCI Australia IMI Select SRI Screened Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.35 % |
Price | $8.25 | $32.53 |
Size | $182.401 million | $188.473 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 4.15 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 02/05/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | GRNV | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 580 |
Median incremental investment | $967.00 | $670.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,905.75 | $1,415.06 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DRUG | GRNV | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | GRNV |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |